Trial Profile
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bococizumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Mar 2014 Primary endpoint 'LDL-cholesterol-level' for bococizumab 150mg q14d has been met according to results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 19 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.